Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP: PHRRF )

0.1600 -0.0025 (-1.54%)
Streaming Delayed Price Updated: 3:06 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 3 Next >
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced... 
Via Benzinga
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and... 
Via Benzinga
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S. 
Via Benzinga
PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing
Ketamine-producer PharmaTher Holdings Ltd. (OTCQB: PHRRF) has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET... 
Via Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
PharmaTher Holdings Ltd. (OTC: PHRRF) continues on its path to becoming the leader in specialty ketamine products. 
Via Benzinga
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Psychedelics policy action took center stage this week. 
Via Benzinga
Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process
The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process. 
Via Benzinga
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. 
Via Benzinga
Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy
Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022. 
Via Benzinga
Ketamine Could Help Treat Parkinson's Disease, Study Finds
PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced positive results from a clinical study of ketamine for the treatment of ... 
Via Benzinga
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
This article was originally published on Micr... 
Via Benzinga
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced... 
Via Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics 
Via Benzinga
Exposures Product Safety
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
The Week In Psychedelics 
Via Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
The Week In Psychedelics: 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
These OTC Securities Had the Most Trading Activity in June
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ: 
Via Benzinga
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ... 
Via Benzinga
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.